Nuclea has entered into a deal with Nuvera Biosciences to jointly create a gene-based test to predict a breast cancer patient's response to endocrine therapy and taxane chemotherapy. The company also struck a deal with AccuGenomics to co-develop and test the use of a BCR-ABL assay in measuring the effectiveness of treatment for chronic myeloid leukemia.

Related Summaries